110 related articles for article (PubMed ID: 26417028)
1. Comparative Proteomics of Tumor and Paired Normal Breast Tissue Highlights Potential Biomarkers in Breast Cancer.
Da Costa GG; Gomig TH; Kaviski R; Santos Sousa K; Kukolj C; De Lima RS; De Andrade Urban C; Cavalli IJ; Ribeiro EM
Cancer Genomics Proteomics; 2015; 12(5):251-61. PubMed ID: 26417028
[TBL] [Abstract][Full Text] [Related]
2. Comparative proteomic analysis of ductal and lobular invasive breast carcinoma.
Oliveira NC; Gomig TH; Milioli HH; Cordeiro F; Costa GG; Urban CA; Lima RS; Cavalli IJ; Ribeiro EM
Genet Mol Res; 2016 Apr; 15(2):. PubMed ID: 27173185
[TBL] [Abstract][Full Text] [Related]
3. Comparative proteomics of primary breast carcinomas and lymph node metastases outlining markers of tumor invasion.
Milioli HH; Santos Sousa K; Kaviski R; Dos Santos Oliveira NC; De Andrade Urban C; De Lima RS; Cavalli IJ; De Souza Fonseca Ribeiro EM
Cancer Genomics Proteomics; 2015; 12(2):89-101. PubMed ID: 25770193
[TBL] [Abstract][Full Text] [Related]
4. Proteomic analysis of non-tumoral breast tissue.
Costa GG; Kaviski R; Souza LE; Urban CA; Lima RS; Cavalli IJ; Ribeiro EM
Genet Mol Res; 2011 Oct; 10(4):2430-42. PubMed ID: 21968807
[TBL] [Abstract][Full Text] [Related]
5. Proteomic analysis of infiltrating ductal carcinoma tissues by coupled 2-D DIGE/MS/MS analysis.
Davalieva K; Kiprijanovska S; Broussard C; Petrusevska G; Efremov GD
Mol Biol (Mosk); 2012; 46(3):469-80. PubMed ID: 22888636
[TBL] [Abstract][Full Text] [Related]
6. Comparative serum proteome analysis of human lymph node negative/positive invasive ductal carcinoma of the breast and benign breast disease controls via label-free semiquantitative shotgun technology.
Hu X; Zhang Y; Zhang A; Li Y; Zhu Z; Shao Z; Zeng R; Xu LX
OMICS; 2009 Aug; 13(4):291-300. PubMed ID: 19624269
[TBL] [Abstract][Full Text] [Related]
7. Comparative proteome analysis of breast cancer and normal breast.
Luo Y; Zhang J; Liu Y; Shaw AC; Wang X; Wu S; Zeng X; Chen J; Gao Y; Zheng D
Mol Biotechnol; 2005 Mar; 29(3):233-44. PubMed ID: 15767701
[TBL] [Abstract][Full Text] [Related]
8. Towards a proteome signature for invasive ductal breast carcinoma derived from label-free nanoscale LC-MS protein expression profiling of tumorous and glandular tissue.
Röwer C; Vissers JP; Koy C; Kipping M; Hecker M; Reimer T; Gerber B; Thiesen HJ; Glocker MO
Anal Bioanal Chem; 2009 Dec; 395(8):2443-56. PubMed ID: 19876624
[TBL] [Abstract][Full Text] [Related]
9. Breast cancer proteomics reveals a positive correlation between glyoxalase 1 expression and high tumor grade.
Fonseca-Sánchez MA; Rodríguez Cuevas S; Mendoza-Hernández G; Bautista-Piña V; Arechaga Ocampo E; Hidalgo Miranda A; Quintanar Jurado V; Marchat LA; Alvarez-Sánchez E; Pérez Plasencia C; López-Camarillo C
Int J Oncol; 2012 Aug; 41(2):670-80. PubMed ID: 22614840
[TBL] [Abstract][Full Text] [Related]
10. PDIA3 and PDIA6 gene expression as an aggressiveness marker in primary ductal breast cancer.
Ramos FS; Serino LT; Carvalho CM; Lima RS; Urban CA; Cavalli IJ; Ribeiro EM
Genet Mol Res; 2015 Jun; 14(2):6960-7. PubMed ID: 26125904
[TBL] [Abstract][Full Text] [Related]
11. Proteome profiling of breast cancer biopsies reveals a wound healing signature of cancer-associated fibroblasts.
Groessl M; Slany A; Bileck A; Gloessmann K; Kreutz D; Jaeger W; Pfeiler G; Gerner C
J Proteome Res; 2014 Nov; 13(11):4773-82. PubMed ID: 25238572
[TBL] [Abstract][Full Text] [Related]
12. Proteomic analysis of breast cancer tissues to identify biomarker candidates by gel-assisted digestion and label-free quantification methods using LC-MS/MS.
Song MN; Moon PG; Lee JE; Na M; Kang W; Chae YS; Park JY; Park H; Baek MC
Arch Pharm Res; 2012 Oct; 35(10):1839-47. PubMed ID: 23139137
[TBL] [Abstract][Full Text] [Related]
13. Proteomics pipeline for biomarker discovery of laser capture microdissected breast cancer tissue.
Liu NQ; Braakman RB; Stingl C; Luider TM; Martens JW; Foekens JA; Umar A
J Mammary Gland Biol Neoplasia; 2012 Jun; 17(2):155-64. PubMed ID: 22644111
[TBL] [Abstract][Full Text] [Related]
14. Novel breast cancer biomarkers identified by integrative proteomic and gene expression mapping.
Ou K; Yu K; Kesuma D; Hooi M; Huang N; Chen W; Lee SY; Goh XP; Tan LK; Liu J; Soon SY; Bin Abdul Rashid S; Putti TC; Jikuya H; Ichikawa T; Nishimura O; Salto-Tellez M; Tan P
J Proteome Res; 2008 Apr; 7(4):1518-28. PubMed ID: 18318472
[TBL] [Abstract][Full Text] [Related]
15. Biomarker discovery in low-grade breast cancer using isobaric stable isotope tags and two-dimensional liquid chromatography-tandem mass spectrometry (iTRAQ-2DLC-MS/MS) based quantitative proteomic analysis.
Bouchal P; Roumeliotis T; Hrstka R; Nenutil R; Vojtesek B; Garbis SD
J Proteome Res; 2009 Jan; 8(1):362-73. PubMed ID: 19053527
[TBL] [Abstract][Full Text] [Related]
16. Serum proteome profiling of primary breast cancer indicates a specific biomarker profile.
Böhm D; Keller K; Wehrwein N; Lebrecht A; Schmidt M; Kölbl H; Grus FH
Oncol Rep; 2011 Nov; 26(5):1051-6. PubMed ID: 21837365
[TBL] [Abstract][Full Text] [Related]
17. Proteomics analysis of human breast milk to assess breast cancer risk.
Aslebagh R; Channaveerappa D; Arcaro KF; Darie CC
Electrophoresis; 2018 Feb; 39(4):653-665. PubMed ID: 29193311
[TBL] [Abstract][Full Text] [Related]
18. Mass spectrometric characterization of protein structure details refines the proteome signature for invasive ductal breast carcinoma.
Röwer C; Koy C; Hecker M; Reimer T; Gerber B; Thiesen HJ; Glocker MO
J Am Soc Mass Spectrom; 2011 Mar; 22(3):440-56. PubMed ID: 21472563
[TBL] [Abstract][Full Text] [Related]
19. Quantitative label-free mass spectrometry using contralateral and adjacent breast tissues reveal differentially expressed proteins and their predicted impacts on pathways and cellular functions in breast cancer.
Gomig THB; Cavalli IJ; Souza RLR; Vieira E; Lucena ACR; Batista M; Machado KC; Marchini FK; Marchi FA; Lima RS; de Andrade Urban C; Cavalli LR; Ribeiro EMSF
J Proteomics; 2019 May; 199():1-14. PubMed ID: 30772490
[TBL] [Abstract][Full Text] [Related]
20. Differential proteomic comparison of breast cancer secretome using a quantitative paired analysis workflow.
Brunoro GVF; Carvalho PC; Barbosa VC; Pagnoncelli D; De Moura Gallo CV; Perales J; Zahedi RP; Valente RH; Neves-Ferreira AGDC
BMC Cancer; 2019 Apr; 19(1):365. PubMed ID: 30999875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
